MX355422B - Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar. - Google Patents
Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar.Info
- Publication number
- MX355422B MX355422B MX2015005910A MX2015005910A MX355422B MX 355422 B MX355422 B MX 355422B MX 2015005910 A MX2015005910 A MX 2015005910A MX 2015005910 A MX2015005910 A MX 2015005910A MX 355422 B MX355422 B MX 355422B
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- dihydroimidazole
- treatment
- lung injury
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 2
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical class SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 title 1
- 208000004852 Lung Injury Diseases 0.000 title 1
- 206010069363 Traumatic lung injury Diseases 0.000 title 1
- 231100000515 lung injury Toxicity 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- -1 hydroxy, nitro, amino Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261726119P | 2012-11-14 | 2012-11-14 | |
| PCT/PT2013/000065 WO2014077715A1 (en) | 2012-11-14 | 2013-11-14 | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005910A MX2015005910A (es) | 2015-08-10 |
| MX355422B true MX355422B (es) | 2018-04-18 |
Family
ID=49759506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005910A MX355422B (es) | 2012-11-14 | 2013-11-14 | Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9604970B2 (OSRAM) |
| EP (1) | EP2919780B1 (OSRAM) |
| JP (1) | JP6373275B2 (OSRAM) |
| KR (1) | KR102259938B1 (OSRAM) |
| CN (1) | CN105025895B (OSRAM) |
| AU (1) | AU2013345494B2 (OSRAM) |
| BR (1) | BR112015010969B1 (OSRAM) |
| CA (1) | CA2890920C (OSRAM) |
| CY (1) | CY1120953T1 (OSRAM) |
| DK (1) | DK2919780T3 (OSRAM) |
| ES (1) | ES2693025T3 (OSRAM) |
| HR (1) | HRP20181651T1 (OSRAM) |
| IN (1) | IN2015DN04089A (OSRAM) |
| LT (1) | LT2919780T (OSRAM) |
| MX (1) | MX355422B (OSRAM) |
| PL (1) | PL2919780T3 (OSRAM) |
| PT (1) | PT2919780T (OSRAM) |
| RS (1) | RS57874B1 (OSRAM) |
| RU (1) | RU2718055C2 (OSRAM) |
| SI (1) | SI2919780T1 (OSRAM) |
| SM (1) | SMT201800560T1 (OSRAM) |
| TR (1) | TR201815850T4 (OSRAM) |
| WO (1) | WO2014077715A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015DN04089A (OSRAM) | 2012-11-14 | 2015-10-09 | BIAL PORTELA & Cª S A | |
| GB201810395D0 (en) * | 2018-06-25 | 2018-08-08 | Bial Portela & Ca Sa | Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation |
| WO2021005623A1 (en) * | 2019-07-08 | 2021-01-14 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera |
| CN118598820B (zh) * | 2024-02-06 | 2025-07-08 | 石家庄四药有限公司 | 一种二苯基三嗪类化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0623107B2 (ja) * | 1990-11-16 | 1994-03-30 | 帝人株式会社 | プロスタサイクリン類を有効成分とする薬学的組成物 |
| HUT76295A (en) * | 1994-04-26 | 1997-07-28 | Syntex Inc | Imidazolyl- and triazolyl-thion derivatives, pharmaceutical compositions containing them and process for producing them |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US7125904B2 (en) * | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| US20040102361A1 (en) * | 2002-11-27 | 2004-05-27 | Frederic Bodin | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| GB0600709D0 (en) * | 2006-01-13 | 2006-02-22 | Portela & Ca Sa | Drug combinations |
| GB0610804D0 (en) * | 2006-05-31 | 2006-07-12 | Portela & Ca Sa | New crystal forms |
| GB0700635D0 (en) * | 2007-01-12 | 2007-02-21 | Portela & Ca Sa | Therapy |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| EP2231648A1 (en) * | 2007-12-05 | 2010-09-29 | BIAL - Portela & Ca., S.A. | New salts and crystal forms |
| JP2011508775A (ja) * | 2008-01-03 | 2011-03-17 | ビオマリン プハルマセウトイカル インコーポレイテッド | Ｂｈ４応答性状態を治療するためのプテリン類似体 |
| AR070841A1 (es) * | 2008-03-13 | 2010-05-05 | Bial Portela & Ca Sa | Proceso de hidrogenacion catalitica asimetrica |
| AR071632A1 (es) * | 2008-05-06 | 2010-06-30 | Bial Portela & Ca Sa | Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa" |
| DE102008054205A1 (de) * | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
| RU2604734C2 (ru) * | 2010-12-22 | 2016-12-10 | БИАЛ-ПОРТЕЛА энд КА., С.А. | Кристаллическая форма и способ ее очистки |
| IN2015DN04089A (OSRAM) | 2012-11-14 | 2015-10-09 | BIAL PORTELA & Cª S A |
-
2013
- 2013-11-14 IN IN4089DEN2015 patent/IN2015DN04089A/en unknown
- 2013-11-14 JP JP2015542997A patent/JP6373275B2/ja not_active Expired - Fee Related
- 2013-11-14 BR BR112015010969-1A patent/BR112015010969B1/pt not_active IP Right Cessation
- 2013-11-14 RU RU2015120164A patent/RU2718055C2/ru not_active Application Discontinuation
- 2013-11-14 KR KR1020157014363A patent/KR102259938B1/ko not_active Expired - Fee Related
- 2013-11-14 CA CA2890920A patent/CA2890920C/en not_active Expired - Fee Related
- 2013-11-14 TR TR2018/15850T patent/TR201815850T4/tr unknown
- 2013-11-14 CN CN201380059547.2A patent/CN105025895B/zh not_active Expired - Fee Related
- 2013-11-14 AU AU2013345494A patent/AU2013345494B2/en not_active Ceased
- 2013-11-14 PT PT13803292T patent/PT2919780T/pt unknown
- 2013-11-14 RS RS20181204A patent/RS57874B1/sr unknown
- 2013-11-14 SI SI201331204T patent/SI2919780T1/sl unknown
- 2013-11-14 DK DK13803292.5T patent/DK2919780T3/en active
- 2013-11-14 WO PCT/PT2013/000065 patent/WO2014077715A1/en not_active Ceased
- 2013-11-14 SM SM20180560T patent/SMT201800560T1/it unknown
- 2013-11-14 ES ES13803292.5T patent/ES2693025T3/es active Active
- 2013-11-14 US US14/441,043 patent/US9604970B2/en not_active Expired - Fee Related
- 2013-11-14 LT LTEP13803292.5T patent/LT2919780T/lt unknown
- 2013-11-14 HR HRP20181651TT patent/HRP20181651T1/hr unknown
- 2013-11-14 EP EP13803292.5A patent/EP2919780B1/en active Active
- 2013-11-14 MX MX2015005910A patent/MX355422B/es active IP Right Grant
- 2013-11-14 PL PL13803292T patent/PL2919780T3/pl unknown
-
2017
- 2017-02-14 US US15/432,616 patent/US10308640B2/en not_active Expired - Fee Related
-
2018
- 2018-10-30 CY CY20181101117T patent/CY1120953T1/el unknown
-
2019
- 2019-04-16 US US16/385,350 patent/US20190241545A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| GB0708818D0 (en) | Compounds | |
| CY1119163T1 (el) | Αμιδια πυριδονης ως ρυθμιστες διαυλων νατριου | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| MD4425B1 (ro) | Alcoxipirazoli în calitate de activatori ai guanilatciclazei solubile | |
| WO2014091298A3 (en) | Nitrogen containing morphinan derivatives and the use thereof | |
| PH12013502463A1 (en) | Trpv4 antagonists | |
| EA201000098A1 (ru) | Производные хиназолинамида | |
| UA108510C2 (xx) | Циклопропанова сполука | |
| PH12018502457B1 (en) | Treatment for parkinson's disease | |
| MY170262A (en) | Dicarboxylic acid compound | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| MX383551B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida | |
| MX355422B (es) | Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar. | |
| NZ702357A (en) | 5,6-benzoflavone compositions for treating and/or preventing skin disease associated with hyperseborrhea | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| WO2012122028A3 (en) | Pyrazinoisoquinoline compounds | |
| MX2011008360A (es) | Derivados de piridazinona sustituida con heteroarilo. | |
| JOP20220125A1 (ar) | مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها | |
| MX2009010225A (es) | Nuevos compuestos 707 y sus usos. | |
| EA201491878A1 (ru) | Замещенные ксантиновые производные | |
| MX2010008196A (es) | Derivados de acido 4-dimetilaminobutirico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |